Ananda Ghosh, an analyst from H.C. Wainwright, maintained the Buy rating on Maze Therapeutics, Inc.. The associated price target remains the same with $60.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ananda Ghosh has given his Buy rating due to a combination of factors, chiefly the strengthening validation around Maze’s SLC6A19 inhibitor program MZE782. Recent patent filings from Pfizer and Otsuka’s Jnana unit, spanning indications such as chronic kidney disease, MASLD/NAFLD, obesity, and metabolic disorders, independently affirm the commercial and scientific relevance of the target, in his view.
Ghosh also notes that preclinical data linking SLC6A19 loss to elevated FGF21 and GLP-1, improved liver fat metrics, and NASH protection support the drug’s broader cardiometabolic potential beyond Maze’s current CKD focus. He believes this expanding addressable market, combined with a differentiated oral mechanism that may offer tolerability advantages versus injectable GLP-1 agonists, makes MZE782 an underappreciated asset that justifies a positive stance on MAZE shares.
In another report released on March 6, Leerink Partners also reiterated a Buy rating on the stock with a $50.00 price target.